Table 2.

Mean observed utilities for RR-DTChealth states and Incremental impact of health states on utilities compared to a base state of stable/no response with no adverse events

Parameter	Observed mean utilitya		Unadjustedb		Adjustedc
	Mean utility (standard deviation)	95% confidence interval	Utility value	95% confidence interval	Utility value	95% confidence interval
Base state – stable/no	0.80 (0.19)	0.77, 0.84	0.86	0.83, 0.90	0.87	0.84, 0.91
response
Response to therapy	0.86 (0.15)	0.83, 0.89	+0.04	0.01, 0.07	+0.04	0.01, 0.07
Progressive disease	0.50 (0.28)	0.45, 0.56	−0.37	−0.43, −0.31	−0.35	−0.41, −0.29
Diarrhea	0.42 (0.29)	0.36, 0.48	−0.48	−0.54, −0.43	−0.47	−0.52, −0.41
Fatigue	0.72 (0.24)	0.67, 0.77	−0.08	−0.13, −0.04	−0.08	−0.12, 0.04
Hand and foot syndrome	0.52 (0.30)	0.46, 0.58	−0.35	−0.42, −0.29	−0.34	−0.40, 0.28
Alopecia	0.75 (0.21)	0.71, 0.79	−0.05	−0.09, −0.01	−0.05	−0.08, 0.01

Notes:

^aMean observed TTO health state utilities.

^bDerived from reduced parameter model (health states only).

^cAdjusted for educational qualification level and EQ-5D-3L (usual activities and anxiety/depression) ratings using UK norms.

Abbreviations: RR-DTC, radioactive iodine-refractory differentiated thyroid cancer; TTO, time trade off.